Senior AIMS Institute Resident Physician Dr. Julianna Giles presents at the the 2021 Oncology Association of Naturopathic Physicians (OncANP) 10th Annual Conference

Senior AIMS Institute Resident Physician Dr. Julianna Giles presents at the the 2021 Oncology Association of Naturopathic Physicians (OncANP) 10th Annual Conferencehttps://oncanp.org/conference/

On June 12, Dr. Giles presented virtually the following oral presentation:

Ketamine assisted psychotherapy (KAP) in the context of advanced cancer diagnosis, treatment, progression and remission

The abstract’s authors are: Julianna Giles, ND, MSAS; Sunil Aggarwal MD, PhD,
FAAPMR; Leanna Standish, ND, PhD, LAc, FABNO

Here is the full text of the abstract:

Cancer is well established as a genetic, metabolic and immunologic disease. At Advanced Integrative Medical Science (AIMS) Institute, we also understand cancer as a disease of psychospiritual stagnation. Entheogenic substances, including ketamine, in part through disruption of the default mode network, have been shown to break through blockages in a patients’ psyche, specifically in treatment-resistant depression, anxiety, and post-traumatic stress disorder (PTSD). These conditions are commonly concomitant with a cancer diagnosis. We examined psychometric measurements of depression (PHQ-9) and anxiety (GAD-7) in ten cancer patients before and after ketamine assisted psychotherapy (KAP) sessions. We also examined objective outcomes in these same patients, defined as either progression, stable disease, no evidence of disease or death.

Data were examined from October 2018 to August 2020. Ten patients fit our criteria of cancer diagnosis and exposure to at least one KAP session. Types of cancer included colorectal cancer, breast cancer, ovarian cancer, prostate cancer, pancreatic cancer, cholangiocarcinoma, anaplastic astrocytoma, oligodendroma and undifferentiated pleomorphic sarcoma. Age at the time of first KAP ranged from 27-63 y (mean 50.4 y, median 53.5 y). 7/10 cancer patients were considered advanced (stage 3 or 4) at the time of first KAP. Four out of 10 patients were NED at the time of KAP intake, 3/10 were stable and 3/10 were progressing. Half (5/10) of the patients were under the care of a psychotherapist while exploring KAP as a therapy. Eight out of ten patients filled out an ACE (adverse childhood events) questionnaire; 2/8 had zero ACEs, 1/8 had one, 2/8 had two, 1/8 had four, 1/8 had five and 1/8 had six. Baseline GAD-7 scores
were obtained for 9/10 subjects; scores ranged from 3-19 (mean 10.22, median 10). Baseline PHQ-9 scores were also obtained for all 10 subjects; scores ranged from 0-14 (mean 6.9, median 7.5). At the end of KAP treatments, 6/10 subjects were NED, 1/10 was stable, 2/10 were progressing and 1/10 was deceased.

Two patients’ data were examined in further detail due to extensive exposure to KAP treatments, which led to self-reported positive outcomes with respect to decreased levels of psychological distress and increased level of functioning; graphical interpretation of the patients’ data follows. Though preliminary data are mixed, we will discuss the utility of KAP implementation in a clinical setting in the context of cancer diagnosis, treatment, progression and remission.

Latest Blog Posts

Watch now: Psychedelics and Grief: When Containment Stops Working 

Watch now: Psychedelics and Grief: When Containment Stops Working 

Supporting women in the wild with science and wisdom about psychedelics. 134. Psychedelics and Grief: When Containment Stops Working Dr. Sunil Aggarwal joins April Pride to talk psilocybin, grief, and the difference between containing a loss and integrating it. April Pride Sep 29 Recently, it occurred to me that my relationship with trust needed tending. When I told a friend, she asked, “Why don’t you trust yourself?” I’ve been sitting with that question because it tracks and it confuses me at the same time. I’ve walked into divorce, entrepreneurship, and work in the Schedule I-adjacent world. Not the choices of ...

Read More
Breakthrough Therapeutics in Complex Illness

Breakthrough Therapeutics in Complex Illness

How Academy Members Are Integrating Psychedelics to Ease Distress Dr. Sunil Aggarwal is quoted in the feature story in the 2026 Fall Quarterly Newsletter from the American Academy of Hospice and Palliative Medicine. For patients facing serious illness, some of the deepest suffering cannot be measured on a numerical scale.  Some patients experience anxiety that does not respond to conventional treatment, as well as a deep sense of demoralization, isolation, and loss of meaning. Palliative and hospice care have long recognized treatment of this existential distress as central to whole-person care. Now, an emerging field of research is asking whether ...

Read More
Psychedelic science update & harm reduction training for naturopathic physicians

Psychedelic science update & harm reduction training for naturopathic physicians

8 CONTINUING EDUCATION (CE) HOURS FEBRUARY 1–4, 2027OPIHIHALE ETHNOBOTANICAL PRESERVEBig Island, Hawai‘i $2,850 INCLUDES Three nights lodging | All mealsGround transportation to and from Kona AirportCourse materials | Guided ethnobotanical tour AIMS Institute in collaboration with Opihihale Ethnobotanical Preserve WHY THIS COURSE? As interest in psychedelic therapies continues to grow, naturopathic physicians are increasingly asked about their safety, effectiveness, legal status, and appropriate clinical use. This immersive continuing education program provides an evidence-based review of current psychedelic science together with practical harm reduction strategies for clinicians whose patients are considering or using psychedelic medicines. Presented by the AIMS Institute in ...

Read More

Accessibility Tools

Increase TextIncrease Text
Decrease TextDecrease Text
GrayscaleGrayscale
Invert Colors
Readable FontReadable Font
Reset
Call Us Text Us